OncoMatch/Clinical Trials/NCT07851025
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Official title: A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-02)
Is NCT07851025 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies multiple treatments including Torvutatug samrotecan and Bevacizumab for epithelial ovarian cancer.
Treatment: Torvutatug samrotecan · Bevacizumab — This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recombination Deficient (HRD) negative advanced ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
Grade: high-grade
newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
completed at least 6 cycles and a maximum of 8 cycles of first-line Platinum-based chemotherapy (PBC) prior to randomisation
Must have received: anti-VEGF therapy (bevacizumab) — in combination with last 3 cycles of PBC, prior to randomisation
must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation
Must have received: cytoreductive surgery
completed cytoreductive surgery or have inoperable disease
Cannot have received: FRα-targeted therapy (MIRV)
Prior exposure to any FRα-targeted therapy, including MIRV
Cannot have received: TOP1i antibody-drug conjugate
Prior exposure to any TOP1i Antibody-drug Conjugate (ADC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Tampa, Florida
- Research Site · Baltimore, Maryland
- Research Site · Billings, Montana
- Research Site · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07851025 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FRα-targeted therapy, TOP1i antibody-drug conjugate disqualifies patients from enrollment.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages